Viroimmunotherapy of Thoracic Cancers

Area of Science:

• Oncology
• Immunology
• Virology

Background:

• Thoracic cancers, including lung cancer and mesothelioma, are leading causes of cancer mortality globally.
• Current immunotherapies, like immune checkpoint inhibitors, benefit only a subset of patients with advanced thoracic cancers.
• Low response rates to existing immunotherapies necessitate the development of novel combination therapies.

Purpose of the Study:

• To review the literature on the application of oncolytic viruses (OVs) in augmenting anti-tumor immune responses for thoracic cancers.
• To explore the potential of virotherapy as a strategy to enhance the efficacy of current immunotherapies.

Main Methods:

• Literature review of studies investigating oncolytic viruses in pre-clinical models of thoracic cancers.
• Analysis of research on the mechanisms by which OVs modulate the tumor microenvironment and immune cell activity.

Main Results:

• Oncolytic viruses selectively infect and kill cancer cells, inducing immunogenic cell death.
• Virotherapy increases immune mediator infiltration into the tumor microenvironment.
• OVs broaden the neoantigen-specific T cell response, potentially enhancing anti-tumor immunity.

Conclusions:

• Oncolytic viruses represent a promising therapeutic strategy for thoracic cancers.
• Combination therapy with oncolytic viruses and immunotherapy may expand the patient population benefiting from immune-based treatments.
• Further research into virotherapy is crucial for developing more effective treatments for thoracic malignancies.